期刊文献+

PTEN和MDM2在非小细胞肺癌中的表达及临床意义 被引量:8

The Expression and Clinical Significance of PTEN and MDM2 in Non-small Cell Lung Cancer
原文传递
导出
摘要 目的:研究PTEN和MDM2在非小细胞肺癌(NSCLC)发生发展中的临床意义。方法:采用免疫组化SP法检测56例非小细胞肺癌组织及20例正常肺组织中PTEN和MDM2蛋白的表达。结果:56例肺癌组织中PTEN表达率为48.21%(27/56),20例正常肺组织中PTEN表达率为95%(19/20),二者有统计学意义(p<0.05)。PTEN表达率与肿瘤的分化程度、临床分期、淋巴结转移有关(p<0.05)。56例肺癌组织中MDM2表达率为53.57%(30/56),20例正常肺组织MDM2表达率为10%(2/20),二者有统计学意义(p<0.05),MDM2表达率与肿瘤的分化程度、临床分期、淋巴结转移有关(p<0.05)。在NSCLC中,PTEN和MDM2的表达呈负相关(p<0.05)。结论:PTEN和MDM2的异常表达在非小细胞肺癌的发生发展过程中起着重要的作用。 Objective: To investigate the expression of PTEN and MDM2 in transitional non-small cell lung cancer(NSCLC).Methods: The expressions of PTEN and MDM2 were determined by immunohistochemical method in 56 cases of primary lung cancer and 20 case of normal lung tissue.Results: The expression of PTEN in 56 cases of lung carcinoma was 48.21% while which was 95% in 20 cases of normal lung tissues(p0.05).The expression of PTEN was related to the degree of cell differentiation,clinical stage and lymph node metastasis.The expression of MDM2 in 56 cases of pulmonary carcinoma was 53.57%,while which was10% in 20 cases of normal lung tissues(p0.05).The expression of MDM2 was related to the degree of tumor cell differentiationclinical stage and lymph node metastasis(p0.05).There was negative correlation between expression of the PTEN and MDM2 in NSCLC(p0.05).Conclusion:Abnormal expression of PTEN,MDM2 may play an important role in the malignant progression of NSCLC.
出处 《现代生物医学进展》 CAS 2011年第6期1128-1131,共4页 Progress in Modern Biomedicine
关键词 PTEN MDM2 非小细胞肺癌 免疫组化 PTEN MDM2 Non-small cell lung cancer Immunohistochemisty
  • 相关文献

参考文献21

  • 1Wu Y, Zhong Z, Huber J. et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer [J]. Clin Cancer Res, 2006,12(21).6573-6584.
  • 2杨海霞,米建强,徐继业,钱婀娜.胃癌组织中mdm2和Rb基因表达及临床意义[J].第四军医大学学报,2007,28(23):2122-2125. 被引量:8
  • 3任义,吴逸明,董海燕,魏立,吴拥军.肺癌组织中MDM2、P53蛋白的表达[J].郑州大学学报(医学版),2005,40(1):67-69. 被引量:9
  • 4Smith I, Procter M, Gellber RD, et al. 2-year follow-up of trastuzumabafter Adjuvant chemotherapy in HER2-positive breast cancer; a ran-domized controlled trial[J]. Lancet, 2007, 369( 9555 )29-36.
  • 5Nahta, YUAN LX, Zhang B, et al. Insulin-like growth factor-lrecep-tor/humanepidermal growth factor receptor 2 helerodimerization con-tributes to trastuzumab resistance of breast cancer cells [J]. CancerRes, 2005;65(23) : 11118-28.
  • 6Robinsion AG, Turbin DT, homosone, et al. Molecular predictive fac- tors in patients receiving trastuzumab-based chemotherapy for metastatic disease[J]. Clin Breast Cancer, 2006;7(3):254-61.
  • 7Tang JM, He QY, Guo RX, et al. Phosphorylated Akt over expresssion and loss of PTEN expression in non-smann cell lung cancer confers poor prognosis[J]. Lung Cancer,2006,51(2): 181-191.
  • 8Goncharuk VN, del-Ronsario A, Kren L, el al.Co-downregulation of PTEN,KAI-I,and nm23-H1 tumor / metastasis suppressor proteins innon-small cell lung cancer[J]. Ann Diagn Pathol, 2004,8(1 ): 6-16.
  • 9Wang C, Yang R, Yue D, et al. Expression of FAK and PTEN in bro- chioloalveolar carcinoma and lung adenocarcinoma [J]. Lung, 2009, 187(2): 104-109.
  • 10Eguehi K, Yao T, Konomoto T, et al. Discordance of p53 mutationsof synchronous coloroetal carcinolnas [J]. Mod Path, 2000,13 (2): 131-139.

二级参考文献33

  • 1姚广裕,杨名添,戎铁华,何萍.MT1-MMP在乳腺癌组织中的表达及临床意义[J].癌症,2004,23(z1):1482-1486. 被引量:10
  • 2李学忠,田军,张立强,潘新良,雷大鹏,解光,栾信庸,王天铎.MDM2与p27在下咽癌中的表达及其临床意义[J].临床耳鼻咽喉科杂志,2004,18(12):716-718. 被引量:2
  • 3吕晓东,王进,王立东,周建炜,李吉林,王俊宽,孙哲,刘小莉,王苒,江亚南,范宗民,高珊珊,何欣.食管贲门双源癌患者癌组织中mdm2与Bcl-2和bax及p53蛋白的表达[J].中华肿瘤防治杂志,2006,13(17):1285-1288. 被引量:12
  • 4强笔,马纪清,邱杰,何金,赵舒薇,郎军添,叶青,王海青.HPV16/18-E6、p53和MDM2蛋白在人喉鳞癌中的表达及相关性研究[J].第二军医大学学报,2006,27(12):1320-1323. 被引量:4
  • 5Cahilly-Snyder L, Yang-Feng T, Francke U, et al. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet, 1987,13(3) :235.
  • 6Lozano G, Montes de Oca Luna R. MDM2 function. Biochem Biophys Acta, 1998, 1 377(2) :M55.
  • 7Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding a p53-associated protein in human sarcoma.Nature, 1992,358(6 381) :80.
  • 8Barak Y, Juven T, Haffner R, et al. mdm2 expression is induced by wild typep53 activity. EMBO J, 1993,12(2):461.
  • 9Shvarts A, Steegenga WT, Riteco N, et al. MDMX: a novel p53-binding protein with some functional properties ofMDM2. EMBO J, 1996,15(19) :5 349.
  • 10Cheng YT, Li YL, Wu JD, et al. Overexpression of MDM2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines. Mol Carcinogenesis, 1995,13 (3) : 173.

共引文献15

同被引文献145

引证文献8

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部